SURVEY PARTICIPANTS
Kathy S Albain, MD
Kimberly L Blackwell, MD
Howard A Burris III, MD
Harold J Burstein, MD, PhD
Lisa A Carey, MD
Rowan T Chlebowski, MD, PhD
Javier Cortes, MD, PhD
Kevin R Fox, MD
Julie R Gralow, MD
Daniel F Hayes, MD
Clifford Hudis, MD
Sara A Hurvitz, MD
Ian E Krop, MD, PhD
Hannah M Linden, MD
John Mackey, MD
Kathy D Miller, MD
Hyman B Muss, MD
Ruth O’Regan, MD
Joyce O’Shaughnessy, MD
Hope S Rugo, MD
Andrew D Seidman, MD
George W Sledge Jr, MD
Ian E Smith, MD
Joseph A Sparano, MD
Sunil Verma, MD, MSEd

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

Are there situations in which you would use T-DM1 combined with pertuzumab outside of a trial?

If a patient had not received pertuzumab in the first-line setting, would you use it in the second line or beyond? If so, in what situations would you use it?

What initial first-line systemic therapy would you generally recommend for an asymptomatic 60-year-old patient with ER-positive, HER2-positive breast cancer and documented liver and lung metastases who has received no prior therapy? The same patient but symptomatic?

What initial first-line systemic therapy, other than bone-directed treatment, would you generally recommend for an asymptomatic 60-year-old patient with ER-positive, HER2-positive breast cancer and several documented bone metastases who has received no prior therapy? The same patient but symptomatic?

What is your usual first-line treatment for patients with HER2-positive, ER-negative metastatic disease who have received no prior therapy?

What is your usual second-line treatment for patients with HER2-positive, ER-negative metastatic disease?

Are there situations in which you would use T-DM1 combined with pertuzumab outside of a trial?

If a patient had not received pertuzumab in the first-line setting, would you use it in the second line or beyond? If so, in what situations would you use it?

What initial first-line systemic therapy would you generally recommend for an asymptomatic 60-year-old patient with ER-positive, HER2-positive breast cancer and documented liver and lung metastases who has received no prior therapy? The same patient but symptomatic?

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists, hematology-oncology fellows, oncology nurses, radiation oncologists, breast/general surgeons and other healthcare practitioners involved in the management of breast cancer.

OVERVIEW OF ACTIVITY
Breast cancer remains the most frequently diagnosed type of cancer in women, with an estimated 234,580 new cases and 40,030 deaths in the United States in 2013. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, and the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease.